Renal function, evaluated as glomerular filtration rate (GFR) and effective renal plasma flow (ERPF), was investigated in 187 pediatric patients who underwent allogeneic (n ¼ 169) or autologous bone marrow transplantation (BMT). Allogeneic BMT patients were divided into three groups: hematological malignancies, aplastic anemia and non-malignant diseases, whereas autologous patients constituted a fourth group. A total of 64% received total body irradiation (TBI) as conditioning therapy, and 50 healthy children served as controls. GFR and ERPF were normal before transplantation. After 1 year, both GFR and ERPF were significantly reduced. GFR had recovered slightly after 3 years and remained stable thereafter. Recovery in ERPF was not apparent. Renal impairment was found in 41% of patients at 1 year, in 31% at 3 years and in 11% 7 years after BMT. Patients with hematological malignancies had lower GFRs than patients with non-malignant diseases at all time points. The most important risk factor as regards chronic renal impairment was TBI. Type of donor, cyclophosphamide (CY), or acute graft-versus-host disease (GVHD) did not seem to contribute to the development of chronic renal impairment. We suggest that tests of renal function should be included in long-term followup after BMT.
Introduction
Bone marrow transplantation (BMT) has improved the prognosis of children with a number of hematological, malignant and metabolic diseases. [1] [2] [3] [4] [5] [6] [7] [8] The growing number of patients who have survived childhood malignancy has increased the importance of monitoring the long-term side effects. Acute renal impairment is a major side effect of BMT, often leading to permanent renal failure. [9] [10] [11] [12] Chronic renal impairment is known to develop with no predisposing acute renal damage. [13] [14] [15] Impaired renal function after BMT is associated with the conditioning regimen before BMT, including intensive chemotherapy and total body irradiation (TBI), and also with prolonged immunosuppression to prevent graft-versus-host disease (GVHD). TBI is considered to be the principal cause of chronic BMT nephropathy, 16 the clinical onset of radiation-induced nephropathy typically developing between 6 and 12 months after initial irradiation. 14 In addition, nephrotoxic antibiotics, infections, cyclosporin A (CyA), amphotericin B, chronic GVHD and cumulative nephrotoxicity during conventional chemotherapy may be factors that are involved in the development of chronic renal failure. 15 Acute renal failure in children following BMT has been investigated relatively well, but long-term renal function has been less intensively studied. 12, [16] [17] [18] In particular, data concerning long-term follow-up of more than 5 years are still needed. We collected information on renal function up to 10 years after BMT in 187 children treated with autologous or allogeneic BMT. The aim of this study was to investigate changes in renal function after BMT, and the long-term outcome as regards renal function.
Patients and methods
Patients. Renal function was evaluated in 187 children who underwent BMT at Karolinska University Hospital, Huddinge, from 1980 to 2000. Data were retrospectively reviewed from patient charts. Most (169; 90%) of the patients underwent allogeneic BMT, and the other 18 patients underwent autologous BMT. Underlying diseases in the allogeneic BMT group are listed in Table 1 . Patients treated with autologous transplantation are listed in one group, regardless of the underlying disease. There were 110 male patients (59%) and 77 (41%) females. Age at the time of BMT was 0.04-17.6 (median 8.0) years. Renal function tests were performed 1-13 times per patient. A total of 50 subjects, 3-22 (median 11) years of age, with no signs of kidney disease served as controls with regard to renal function. The study was approved by the local human research ethics committee at Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Donor histocompatibility
Most patients received transplants from an HLA A, B, DRB1-compatible sibling (n ¼ 104, 61%). Others received syngeneic (n ¼ 4, 2%) matched related (n ¼ 4, 2%) or unrelated (n ¼ 27, 16%) grafts, whereas a small number of patients received one antigen mismatched related (n ¼ 10, 6%) or unrelated (n ¼ 20, 12%) grafts. For class I and II antigens, HLA typing was performed serologically, and when they became available around 1990, genomic methods were used for confirmation. Eighteen patients received autologous grafts.
Stem cell source
Non-manipulated bone marrow was used as stem cell source with the exception of recipients of mismatched grafts, who received T cell-depleted (TCD) marrow.
Conditioning
Patients with leukemia were prepared with cyclophosphamide (CY; 60 mg/kg/day for 2 days; total dose 120 mg/kg) and busulfan (BU; 1 mg/kg Â 4/day for 4 days; total dose 16 mg/kg) or 10 Gy of single fraction TBI usually delivered at 7-8 cGy/min. Fractionated TBI was introduced in 1996, and thereafter some patients received 12-14.4 Gy of fractionated TBI instead of single fraction TBI. A total of 119 patients (64%) received TBI. Lung shielding was used in all patients conditioned with TBI. Antithymocyte globulin (ATG) or other anti-T-cell antibodies were given before BMT to patients with unrelated donors. Patients with severe aplastic anemia (SAA) were prepared with CY at 50 mg/kg/day for 4 days (total dose 200 mg/kg) and ATG. Patients with inborn errors of metabolism received BU at 4 mg/kg/day for 4 days, followed by 4 days of CY at 50 mg/kg/day. In patients with hemophagocytic lymphohistiocytosis (HLH), leukemia in incomplete remission or Philadelphia chromosome-positive ALL, etoposide (900 mg/m 2 ) was added.
Post-BMT immunosuppression and supportive care
Cyclosporin A (CsA) was given as GVHD prophylaxis in combination with a short course of i.v. methotrexate in most children. A few children received single therapy with either CsA or methotrexate (MTX). After 3-6 months the CsA level was tapered and withdrawal was initiated between 9 and 12 months in most cases. Prolonged treatment was given to patients with SAA, inborn errors of metabolism or chronic GVHD. Patients with ALL, AML M4 or M5 were given intrathecal prophylaxis with MTX or cytarabine. Antimicrobial prophylaxis included trimetoprim-sulfamethoxazole, fluconazole and acyclovir to herpes simplex virus (HSV) sero-positive patients. Since 1992, preemptive treatment with ganciclovir or foscarnet has been given for 2-3 weeks to patients with positive CMV-DNA in peripheral blood leukocytes.
Renal function tests
Renal function was evaluated as glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) determined by the clearances of inulin (Inutest, 25%, Laevosan Gesellschaft, Linz, Austria) and paraaminohippuric acid (PAH, aminohippurate sodium, 20%, MSD, West Point, NJ), respectively. A standard clearance technique was used, with continuous infusion after a prime dose. 19 Water diuresis was induced by oral ingestion of 20 ml water/kg body weight during the first hour and then 5 ml/kg body weight every 30 min. After an equilibration time of 1 h, four 30-min urine samples were collected and midway through each collection period a blood sample was drawn. The clearance values presented are the means of the four clearance periods. Investigations in the youngest children (o2 years of age) were performed with a single injection of inulin and PAH, after which blood samples were drawn regularly during the next 180 min and clearance was calculated by means of the two-compartment method. Clearance determinations using the single injection technique give somewhat higher GFR values than those with the water diuresis method. During the last few years, PAH has not been available, which means that sometimes the number of investigations of GFR and ERPF differ.
Statistics
The patient groups used in statistical analyses are presented in Table 1 . Statistical analyses were conducted using Statistica 7.0 software (StatSoft Inc., Tulsa, OK, USA) and SAS System 8.2 (SAS Institute Inc., Cary, NC, USA).
In comparisons of patients and controls before BMT and after 1 year, the Mann-Whitney U-test was used. For comparisons between controls and different groups of diagnoses, Kruskal-Wallis analysis of variance (ANOVA) by ranks followed by multiple comparisons between groups based on ranks were performed.
For comparisons over time, two-way ANOVA for repeated measures was performed using the procedure MIXED in SAS System 8.2 (a model that contains both fixed and random events). Several models were analyzed, taking into account different between-effect factors, diagnoses, types of BMT, CY and TBI. Residuals from the models were positively skewed, especially for the variable ERPF, and therefore these data were logarithmically transformed to meet the requirements for adequate ANOVA.
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Results
Among the 187 patients, 415 clearance tests were performed. By the time of the last clearance test, 124 patients (66%) were alive and 63 (34%) had died. Of the deceased patients, the cause of death was transplantationrelated in 28 cases (44%) and due to disease progression or relapse in 35 (56%) of the cases. None of the patients received a renal transplant; two patients were treated with dialysis because of multi-organ failure in the initial posttransplant period.
All patients (allogeneic and autologous transplants)
Comparison of renal function by type of BMT. Most patients (169; 90%) received allogeneic transplants and 18 patients (10%) received autologous transplants. No differences in GFR or ERPF were noted between autologous and allogeneic transplant patients, either before or after BMT.
Comparison of renal function between patients treated with, or without, CY. One hundred and twenty-nine patients (69%) received CY in their conditioning regimen and 58 patients (31%) did not. No significant difference in either GFR or ERPF was found before BMT or during follow-up between these two groups.
Allogeneic BMT
Comparison of renal function between groups before BMT. Before transplantation, the 67 patients with hematological malignancies had lower GFRs than did the controls (108733 vs 116711 ml/min per 1.73 m 2 , P ¼ 0.02, Figure 1 ), but the mean GFR in this group was still within the normal range, as was the mean ERPF (590 ml/min per 1.73 m Changes in renal function pre-BMT to 1 year after BMT in the 59 patients investigated on both occasions. Both GFR and ERPF were significantly reduced 1 year after BMT compared to the situation before BMT (Po0.0001). When analyzing the changes in the different diagnosis groups, GFR was decreased significantly in all groups. However, ERPF decreased only in the hematological malignancy group (Po0.01) (Figure 2a and b) . . The mean GFR 1 year after BMT also differed from that in the controls (Po0.001). One year after transplantation there were 37 patients (41%) with renal impairment, defined as GFR o80 ml/min/ 1.73 m 2 . Three years after transplantation a slight but statistically significant recovery in GFR after the initial fall was seen (P ¼ 0.04), after which it remained stable (Figure 3a) . Renal impairment was noted in 31% of the patients 3 years after BMT, in 11% of the patients 7 years after BMT and in 23% of the patients 10 years after BMT.
Comparison of renal function between diagnosis groups after BMT. There was a difference in GFR but not in ERPF between patients with hematological malignancies and those with non-malignant diseases at all time points. In patients with hematological malignancies, GFR was significantly lower than in those with non-malignant diseases (P ¼ 0.01) (Figure 4 ).
Influence of TBI on renal function in patients after allogeneic BMT. The majority (169) of patients were treated with allogeneic BMT. Of these, TBI status was available in 168 cases. One hundred and fifteen patients (68%) received TBI (TBI þ group) and 53 patients (32%) did not (TBIÀ group). There was no significant difference in GFR or ERPF between the TBIÀ and TBI þ groups before BMT. After BMT, both GFR and ERPF were reduced in both groups compared with the values beforehand (Po0.0001). In the TBI þ group, the fall in GFR and ERPF was more profound than in the TBIÀ group at all time points (P ¼ 0.02) (Figure 5a and b) .
Influence of donor type on renal function. No difference in GFR or ERPF was found between donor types (matched vs mismatched) at any time point.
Influence of acute GVHD on renal function. Patients were divided into two groups according to grade of acute GVHD: group 1: GVHD grade 0-I (n ¼ 135); group 2: grade II-IV GVHD (n ¼ 22). In a third group, the grade was not known (n ¼ 30). No difference in GFR or ERPF between any of these groups was found at any time point (P ¼ 0.74).
Discussion
GFR was evaluated by the inulin clearance method, which is considered to be the gold standard. 22 Most previous studies concerning renal function following BMT are based on assessment of serum creatinine levels, 15, 23 or prediction of GFR from serum creatinine levels using formulae, 9, 10, 17, 18, 24, 25 or estimation of GFR by way of endogenous creatinine clearance. 26 GFR has only been measured by more accurate methods, such as 51 Cr-EDTA 16, 27 and single-shot inulin clearance in a few studies. 28 In this study, we show the changes in renal function following BMT as detected by means of an inulin clearance method involving a continuous infusion technique.
We found significant falls in GFR and ERPF when comparing the figures pre-BMT and 1 year after BMT. The reduction remained constant during 10 years of follow-up. Forty-one percent of the patients studied had renal impairment (GFRo80 ml/min/1.73 m 2 ) 1 year after transplantation. Patients with a malignant hematological disease as their underlying diagnosis had even lower GFRs. These findings are consistent with a previous report from our unit, 29 when a significant decrease in ALL and AML patients 1 year after BMT was reported. Patzer et al. 28 reported a significant decrease in GFR 1 year after hematological stem cell transplantation (HSCT), which was still within the normal range and which remained unchanged 2 years after HSCT. Kist-van Holthe et al. 10 also reported that mean GFR was decreased (from 110 to 85 ml/min/1.73 m 2 ) 1 year after BMT, but after the first year no further decrease occurred.
Chronic renal insufficiency is a known complication of BMT. Subclinical renal dysfunction has been reported to be common; 56% of patients have been reported to have a 420% decrease in GFR during long-term follow-up after BMT. 17 We found similar results, as in our patients, 54% had a 420% decrease in GFR 7 years after BMT. It has been reported that currently 5-28% of long-term BMT survivors will develop chronic renal dysfunction. 10, 14, 15, [23] [24] [25] 28 This is in accordance with our results, as we found that 11% of the patients had a GFR o80 ml/ min/1.73 m 2 7 years after BMT. Acute renal failure occurs more often than chronic renal failure, with an incidence of 15-34%. 10, 30 According to some reports there is a correlation between acute and chronic renal insufficiency after BMT. 9, 10 Several other authors, however, have not found that acute renal impairment predicted chronic renal failure. 15, 16, 28 There are several risk factors as regards the development of chronic renal impairment following BMT. First, renal function may already be compromised before BMT, since most patients with malignant disease will have been exposed to potentially nephrotoxic chemotherapy, antibiotics or fungostatics. 15, 24, [26] [27] [28] 31 This might be an explanation for the reduced GFR found in our patients with hematological malignancies. However, renal impairment may develop after BMT even though renal function has been within normal limits before the event. 13 Second, BMT is associated with several factors that may be harmful as regards renal function.
The most important risk factor as regards the development of renal impairment following BMT is pretreatment with TBI. Radiation nephropathy is defined as renal injury caused by ionizing radiation. The clinical onset of BMT nephropathy is between 6 and 12 months after irradiation, since the kidney is a late-responding tissue. 14, 15, 23, 26, 32, 33 Morphological studies in patients with radiation nephropathy show mesangiolysis and loss of endothelial cells. 14 Frisk et al. 16 showed that TBI was the principal cause of deterioration in renal function after BMT in pediatric patients treated by means of autologous BMT. Reduction in GFR and ERPF in patients treated with TBI was detected 6 months after BMT, and after the initial decrease, GFR and ERPF remained essentially unchanged. 16 This is consistent with our findings, although most of our patients were treated by means of allogeneic BMT. There are several reports indicating that TBI is of importance in both autologous and allogeneic BMT patients. 15, 17, 25, 26 Lawton et al. 24 showed that renal shielding was protective as regards from BMT nephropathy in adult patients, suggesting that radiation has a major influence in the development of renal impairment. Kist-van Holthe et al. 9 did not find TBI to be a risk factor for chronic renal insufficiency, possibly because their patients received relatively low radiation doses.
To evaluate whether conditioning chemotherapy is involved in the deterioration of renal function, we analyzed the effect of CY in the conditioning regimen. CY is widely used in conditioning, but there are no data regarding its effect on renal function. 25 We found no correlation between the use of CY and development of chronic renal impairment.
Renal dysfunction after allogeneic BMT has been shown to be strongly related to the presence of acute or chronic GVHD. 25 In contrast, Kist-van Holthe et al. 10 found a beneficial effect of GVHD on renal function in BMT recipients. In our patients, we found no difference in the development of chronic renal impairment between cases with no, or very mild acute GVHD vs those with clinically significant acute GVHD. Leblond et al. 17 and Borg et al. 23 also found no link between GVHD and late renal dysfunction. Leblond et al. 17 found no significant difference in GFR or ERPF between patients who underwent allogeneic BMT and who did or did not receive cyclosporin A (CsA) for at least 6 months. Van Why et al. 15 found that 50% of patients who received CsA for 60 days developed renal insufficiency. Noel et al. 31 pointed out that the use of CsA contributes markedly to the occurrence of acute renal failure, but chronic CsA nephrotoxicity is rarely encountered because CsA is usually withdrawn at 6 months. We did not carry out any analysis concerning CsA, as almost all patients were treated with CsA, and it was withdrawn at 9-12 months in most cases. This might be an explanation for the slight increase in GFR between 1 and 3 years after BMT.
Leblond et al. 17 reported that GFR was significantly lower in their allogeneic BMT group than in the autologous group during 2 years of follow-up. We found no difference in this regard. The autologous BMT group included a heterogeneous group of diagnoses, apart from solid tumors (neuroblastoma, rhabdomyosarcoma), including the ones for which auto-BMT is no longer generally used (ALL, AML, lymphoma).
In conclusion, in our pediatric patients a conditioning regimen involving TBI was a risk factor as regards the development of chronic renal impairment following BMT. We found no correlation between the development of chronic renal insufficiency and type of BMT, presence of acute GVHD, CY in the conditioning regimen, or type of donor. In our study, glomerular function tests were performed with the 'gold standard' method using continuous infusion of inulin and PAH. However, in clinical practice, these methods are usually not available and other methods such as iohexol clearance or isotope methods such as 99m Tc-DTPA or 51 Cr-EDTA may therefore also be used. Another method of following renal function could be by (a simple blood sample) cystatin C. The patients at highest risk of long-term renal insufficiency are those transplanted because of a hematological malignancy, and especially those conditioned with TBI. The decrease in GFR is usually found 1 year after transplant and remains relatively stable. We therefore recommend that the renal function test should be performed before the transplant and 1 year after BMT. If the GFR is clinically significantly reduced, the assessment could be repeated after 1-3 years.
